Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in Relapsed or Refractory Peripheral T Cell Lymphoma
NCT04444141Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- May 2020
- Primary completion
- Sep 2022
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in peripheral T-cell lymphoma (PTCL), sponsored by Akeso, Inc.. Started May 2020; status: terminated.
02
Drugs
cadonilimab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04444141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444141.